Do treatments for cardiac amyloidosis stop fibril production and remove existing deposits from the heart?
It depends on the type of amyloidosis and the treatment used. Here's what different treatments can do:
For AL Amyloidosis
Chemotherapy and immunomodulators target abnormal plasma cells that produce the proteins Show Full Answer
Do treatments for cardiac amyloidosis stop fibril production and remove existing deposits from the heart?
It depends on the type of amyloidosis and the treatment used. Here's what different treatments can do:
For AL Amyloidosis:
Chemotherapy and immunomodulators target abnormal plasma cells that produce the proteins forming amyloid fibrils. These treatments aim to kill and slow the growth of those cells, which can stop or reduce new fibril production.
For ATTR Amyloidosis:
Several FDA-approved medications work to prevent new amyloid deposits from building up in the heart:
- Tafamidis (Vyndamax/Vyndaqel)
- Acoramidis (Attruby)
- Vutrisiran (Amvuttra)
These medications can slow disease progression by stopping new fibril formation.
Removing Existing Fibrils:
Current treatments like tafamidis can slow the disease but cannot remove proteins already deposited in the heart. However, a new experimental drug (ALXN2220) is being studied for its ability to actually clear existing amyloid deposits from the heart, which may reverse heart damage. This is still in early trials and not yet available as a standard treatment.
Bottom Line:
Existing treatments focus on stopping new fibril production and managing heart damage, but they don't typically remove fibrils already in the heart. Research into clearing existing deposits is ongoing and shows promise.
November 8, 2025
Join
Your Privacy Choices
